Trop-2 is a novel target for solid cancer therapy with sacituzumab govitecan (IMMU-132), an antibody-drug conjugate (ADC)*-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Trop-2 is a novel target for solid cancer therapy with sacituzumab govitecan (IMMU-132), an antibody-drug conjugate (ADC)*

Published:2015-06-18 Issue:26 Volume:6 Page:22496-22512
ISSN:1949-2553
Container-title:Oncotarget
language:en
Short-container-title:Oncotarget

Author:

Goldenberg David M.¹,Cardillo Thomas M.¹,Govindan Serengulam V.¹,Rossi Edmund A.¹,Sharkey Robert M.¹

Affiliation:

1. Immunomedics, Inc., Morris Plains, NJ, USA

Publisher

Impact Journals, LLC

Subject

Oncology

Cited by 327 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A single-chain fab derived drug conjugate for HER2 specific delivery;Biomaterials;2025-02

2. Acid-sensitive prodrugs; a promising approach for site-specific and targeted drug release;European Journal of Medicinal Chemistry;2024-10

3. Sacituzumab-govitecan in metastatic triple-negative breast cancer: a multicenter effectiveness and safety study;Future Oncology;2024-09-12

4. On the shoulder of ADC: The development of 124I-IMMU-132, an iodine-124-labelled Trop-2-targeting molecular probe for micro-PET imaging;Biomedicine & Pharmacotherapy;2024-09

5. Structural modification strategies of triazoles in anticancer drug development;European Journal of Medicinal Chemistry;2024-09

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP